Overview

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Mirati Therapeutics Inc.
Treatments:
Mocetinostat